Aurobindo Pharma’s wholly owned subsidiary -- Helix Healthcare B.V, has entered into a binding agreement on December 22, 2025 with Shandong Luoxin Pharmaceutical Group Stock Co., China (Shandong Luoxin), the joint venture partner in Luoxin Aurovitas Pharma (Chengdu) Co., China (Luoxin Aurovitas), a 30:70 joint venture company between Helix and Shandong Luoxin, to acquire 20% additional ownership in Luoxin Aurovitas.
The object of acquisition is to expand the manufacturing to economies of scale by adding 2 high Speed Lines and cater market demand. Cost of acquisition is $5.12 million.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: